Company Overview - BioStem Technologies, Inc. is a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care [5] - The company utilizes its proprietary BioREtain processing method to maintain growth factors and preserve tissue structure in its allografts [5] Market Position and Opportunities - Jason Matuszewski, Chairman and CEO, will present BioStem's current position in the chronic wound care market and key opportunities for growth at the Advanced Wound Care Summit on July 15, 2025 [1] - The company aims to drive continued growth in its core allograft business while pursuing opportunities to expand its portfolio across the continuum of care [8] Event Details - The Advanced Wound Care Summit will take place from July 15 to 17, 2025, bringing together global leaders in wound care innovation and clinical research [3] - The summit will feature keynote presentations, interactive panels, and strategic networking opportunities to address unmet needs in chronic wound management [3] Quality and Compliance - BioStem's quality management systems and standard operating procedures are accredited by the American Association of Tissue Banks (AATB) and adhere to Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP) [6] - The company's products are processed at an FDA registered and AATB accredited site in Pompano Beach, Florida [6]

POMPANO BEACH, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that the company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami. Jason Matuszewski, the Company’s CEO, will participate in a fireside chat and will be available for one-on-one meetings. For conferen ...

Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the futurePOMPANO BEACH, Fla., May 22, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (the “Company” or “BioStem”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that Jason Matuszewski, CEO of BioStem is an Ernst & Young LLP (EY US) finalist for the prestigious Entrepreneur Of The Year 2025 Florida Award. No ...

Preliminary net revenue increased 73% to $72.5 million for Q1 2025, compared to $41.9 million in Q1 2024Achieved preliminary GAAP net income of $4.5 million, or $0.27 per shareReported preliminary Q1 2025 Adjusted EBITDA of $7.8 millionQuarter-end cash balance of $26.7 million, up from $22.8 million as of December 31, 2024Financial results conference call and webcast to be held on May 12, 2025 at 4:30 pm ET POMPANO BEACH, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (the “Co ...

Company to co-exhibit with strategic partner Venture Medical, LLC, highlighting collaborative innovation in chronic wound care managementThree accepted scientific posters will feature BioStem’s advanced allograft portfolio POMPANO BEACH, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced its agenda for the Symposium for ...

Conference call and webcast to be held at 4:30 PM ETPOMPANO BEACH, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces it will release its first quarter 2025 financial results on Monday, May 12, 2025, and will host a conference call and webcast at 4:30 PM ET. The webcast will feature an overview of the quarter from Jason Matusz ...